NCT03157167 2025-03-05
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
Navidea Biopharmaceuticals
Phase 1 Completed
Clinical Trials
9 trialsNCT02509598 2024-06-28
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Cardinal Health 414, LLC
Phase 2 Completed
NCT03405142 2022-11-10
Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer
Stanford University
Phase 2 Completed
NCT01902953 2021-06-23
Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
Maimonides Medical Center
Phase 2 Completed
NCT02287675 2020-07-28
Lymphoseek
Kettering Health Network
Phase 4 Completed
NCT02065232 2019-08-14
Sentinel Lymph Node Mapping Post-Injection Site Pain
University of California, San Diego
Completed
NCT02201420 2016-09-27
Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
Navidea Biopharmaceuticals
Phase 2 Completed
NCT00671918 2013-06-17
Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
Navidea Biopharmaceuticals
Phase 3 Completed
NCT01106040 2013-06-17
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Navidea Biopharmaceuticals
Phase 3 Completed